SHANGHAI – Looking to lower costs and facilitate better health care outcomes, China is stepping up efforts to develop a regulatory framework and a market for biosimilars.

SHANGHAI – An unexpectedly strong second quarter has boosted investor interest in little-known Sinovac Biotech Ltd., a Beijing-based vaccine maker listed on Nasdaq.

SHANGHAI – Looking to lower costs and facilitate better health care outcomes, China is stepping up efforts to develop a regulatory framework and a market for biosimilars.

SHANGHAI – An unexpectedly strong second quarter has boosted investor interest in little-known Sinovac Biotech Ltd., a Beijing-based vaccine maker listed on Nasdaq.

SHANGHAI – Highlighting increasing public concern over drug, device and food safety in China, a crackdown on illegal pharmaceutical advertising has led to a dramatic increase in the number of reported cases.

SHANGHAI – Highlighting increasing public concern over drug, device and food safety in China, a crackdown on illegal pharmaceutical advertising has led to a dramatic increase in the number of reported cases.

SHANGHAI – Multinational drug companies may have to deal with much greater oversight of their pricing policies in China as regulators sharpen their focus and work to bring down costs for patients.

SHANGHAI – The announcement that China's largest pharmaceutical company will build the country's largest biotechnology research center in Wuhan is cementing the reputation of the Chinese city as a global biotech center. China National Pharmaceutical Group Corp. (Sinopharm) plans to build the center at the Wuhan National Bioindustry Base, also known as Biolake, in the city of Wuhan in Hubei Province.

SHANGHAI -–The travails of Zhejiang Hangzhou Xinfu Pharma, a small Chinese biotech firm that lost money several years running, are a clear warning to investors.